Last reviewed · How we verify
Riv (riv)
RIV, developed by Pfizer Inc., is a marketed drug for HIV-1 infection treatment. It is used in combination with other antiretroviral agents in pediatric patients. The drug has generated significant revenue of 63.6B. RIV has undergone 12 trials and has been published in 371 studies. Its clinical differentiation and commercial significance are notable in the pharma industry. However, pipeline developments for similar treatments may impact its market share.
At a glance
| Generic name | riv |
|---|---|
| Sponsor | Pfizer |
| Drug class | Protease Inhibitors |
| Target | HIV-1 protease |
| Modality | Vaccine |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- HIV-1 infection
- HIV-1 infection in combination with other antiretroviral agents
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less
- HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater
Common side effects
- Injection site pain (PAIN AT THE INJECTION SITE) left deltoid
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Myalgia (NEW OR WORSENED MUSCLE PAIN)
- Injection site pain (PAIN AT THE INJECTION SITE) right deltoid
- Injection Site Pain
- Injection Site Tenderness
- Injection site swelling (SWELLING) left deltoid
- Chills (CHILLS)
- Injection site erythema (REDNESS) left deltoid
- Diarrhoea (DIARRHEA)
- Arthralgia (NEW OR WORSENED JOINT PAIN)
Drug interactions
- Atorvastatin
- Cyclosporine
- Digoxin
- Ergot alkaloids
- Fentanyl
- Ketoconazole
- Midazolam
- Omeprazole
- Pimozide
- Quinidine
- Rifampicin
- Theophylline
Key clinical trials
- A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults (PHASE2)
- Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (PHASE1)
- Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age (PHASE1)
- Immunogenicity of Influenza Vaccinations (PHASE4)
- Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.
- Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older (PHASE1, PHASE2)
- Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years (PHASE4)
- Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Riv CI brief — competitive landscape report
- Riv updates RSS · CI watch RSS
- Pfizer portfolio CI